--- title: "Phathom Pharmaceuticals (PHAT) news: offering" url: "https://aibio.space/companies/phathom-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PHAT offering news: Phathom Pharmaceuticals prices stock and pre-funded warrant offering at $16.00 a share. Phathom Pharmaceuticals, Inc." --- PHAT Phathom Pharmaceuticals, Inc. NASDAQ · United States # Phathom Pharmaceuticals (PHAT) news PHAT offering news Financings · 2026-01-07 ## [Phathom Pharmaceuticals prices stock and pre-funded warrant offering at $16.00 a share](https://aibio.space/news/phathom-pharmaceuticals-prices-stock-pre-funded-warrant-offering-16-00/) Phathom priced 6,875,000 shares at $16.00 plus pre-funded warrants for 1,250,078 shares, for a public offering of $129,999,998. Its cash fell from $297.3 million at the end of 2024 to a preliminary $130 million at the end of 2025, and the company expects operating profit only in the second half of 2026, excluding stock-based compensation. ## Latest Phathom Pharmaceuticals news We have not published a story on Phathom Pharmaceuticals yet. When there is news, it will appear here. ## Phathom Pharmaceuticals at a glance - **Ticker**: PHAT - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $184.6 million ### Related companies - [Journey Medical](https://aibio.space/companies/journey-medical/) NASDAQ: DERM - [Perrigo Company](https://aibio.space/companies/perrigo/) NYSE: PRGO - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN - [Genelux](https://aibio.space/companies/genelux/) NASDAQ: GNLX - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) NASDAQ: RPRX - [PTC Therapeutics](https://aibio.space/companies/ptc-therapeutics/) NASDAQ: PTCT - [Indaptus Therapeutics](https://aibio.space/companies/indaptus-therapeutics/) NASDAQ: INDP - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) NASDAQ: ALNY ### Also on NASDAQ - [CareDx](https://aibio.space/companies/caredx/) CDNA - [LENSAR](https://aibio.space/companies/lensar/) LNSR - [ICON](https://aibio.space/companies/icon/) ICLR - [SkinHealth Systems](https://aibio.space/companies/skinhealth-systems/) SKIN - [Relmada Therapeutics](https://aibio.space/companies/relmada-therapeutics/) RLMD - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) ACAD ## What Phathom Pharmaceuticals does Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on commercializing and developing treatments for gastrointestinal diseases. Its approved products, VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, contain vonoprazan, an oral potassium-competitive acid blocker. The company says VOQUEZNA is the only PCAB approved for marketing and sale in the United States. Phathom began U.S. commercialization in November 2023, with VOQUEZNA for erosive gastroesophageal reflux disease and H. pylori infection, and the two PAK products for H. pylori infection. The FDA approved VOQUEZNA for relief of heartburn associated with non-erosive GERD in July 2024. Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited, from which Phathom licensed U.S., European and Canadian rights in 2019. Phathom independently commercializes its products in the United States. Most of its revenue in 2025 came from VOQUEZNA sales, and the company reports growth in prescription volume and prescriber adoption. | Product or program | What it is | Stage | |---|---|---| | VOQUEZNA | Vonoprazan acid blocker for erosive GERD and H. pylori infection | Approved in the US | | VOQUEZNA DUAL PAK and TRIPLE PAK | Vonoprazan packs for H. pylori infection | Approved in the US | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm). ## Phathom Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$175.1 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | [$55.3 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | | Research and development | [$32.8 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | [$34.1 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | | Net income (loss) | [-$221.2 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | [-$334.3 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | | Cash from operations | [-$166.8 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | [-$266.8 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | | Cash and equivalents | [$130.0 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/) | [$297.3 million](https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $184.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Phathom Pharmaceuticals Has Phathom Pharmaceuticals raised money recently? Our latest story on this, dated Jan 7, 2026: "Phathom Pharmaceuticals prices stock and pre-funded warrant offering at $16.00 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/phathom-pharmaceuticals-prices-stock-pre-funded-warrant-offering-16-00/). What is the ticker symbol of Phathom Pharmaceuticals? Phathom Pharmaceuticals, Inc. trades under the ticker PHAT on NASDAQ. Where is Phathom Pharmaceuticals listed? Phathom Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Phathom Pharmaceuticals? The SEC Central Index Key (CIK) for Phathom Pharmaceuticals, Inc. is 1783183. Its filings are on SEC EDGAR. How many shares does Phathom Pharmaceuticals have outstanding? 80,900,934 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-30. Which country or territory is Phathom Pharmaceuticals listed under? Our directory records Phathom Pharmaceuticals, Inc. under United States. What does Phathom Pharmaceuticals do? Our directory classifies Phathom Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Phathom Pharmaceuticals? The ISIN recorded for Phathom Pharmaceuticals, Inc. is US71722W1071. Does aibio.space cover Phathom Pharmaceuticals? aibio.space lists Phathom Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Phathom Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Phathom Pharmaceuticals develop? Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on commercializing and developing treatments for gastrointestinal diseases. Its approved products, VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, contain vonoprazan, an oral potassium-competitive acid blocker. What is VOQUEZNA from Phathom Pharmaceuticals? VOQUEZNA: Vonoprazan acid blocker for erosive GERD and H. pylori infection Stage: Approved in the US. What is VOQUEZNA DUAL PAK and TRIPLE PAK from Phathom Pharmaceuticals? VOQUEZNA DUAL PAK and TRIPLE PAK: Vonoprazan packs for H. pylori infection Stage: Approved in the US. What was Phathom Pharmaceuticals's revenue last year? $175.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Phathom Pharmaceuticals profitable? Phathom Pharmaceuticals, Inc. reported a net loss of $221.2 million for the fiscal year ended Dec 31, 2025, and used $166.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Phathom Pharmaceuticals Members talk about Phathom Pharmaceuticals (PHAT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Phathom Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-01-07 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1783183/000119312526006403/d92211d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PHAT on TradingView](https://www.tradingview.com/symbols/NASDAQ-PHAT/). ## SEC filings and registration - **SEC name**: Phathom Pharmaceuticals, Inc. - **CIK**: 1783183 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PHAT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 CAMPUS DRIVE,, FLORHAM PARK, NJ, 07932 - **Phone**: (877) 742-8466 - **Shares outstanding**: 80,900,934 as of 2026-07-27 (10-Q filed 2026-07-30) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000119312526324867/phat-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879d8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526234379/d227860d8k.htm) filed 2026-05-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1783183/000119312526193946/phat-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332d8k.htm) filed 2026-04-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1783183/000119312526144570/phat-20260406.htm) filed 2026-04-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001783183), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Phathom Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PHAT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Phathom Pharmaceuticals, Inc. - **Ticker**: PHAT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US71722W1071 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PHAT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/phathom-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Phathom Pharmaceuticals (PHAT) news: offering", 2026-10-31, https://aibio.space/companies/phathom-pharmaceuticals/